

Alain Faivre-chauvet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9023847/publications.pdf>

Version: 2024-02-01

74
papers

2,081
citations

186265

28
h-index

265206

42
g-index

78
all docs

78
docs citations

78
times ranked

2224
citing authors

#	ARTICLE	IF	CITATIONS
1	Investigation on the reactivity of nucleophilic radiohalogens with arylboronic acids in water: access to an efficient single-step method for the radioiodination and astatination of antibodies. <i>Chemical Science</i> , 2021, 12, 1458-1468.	7.4	18
2	Cyclam-Based Chelators Bearing Phosphonated Pyridine Pendants for ⁶⁴ Cu-PET Imaging: Synthesis, Physicochemical Studies, Radiolabeling, and Bioimaging. <i>Inorganic Chemistry</i> , 2021, 60, 2634-2648.	4.0	13
3	Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1221-1227.	5.0	12
4	Copper-64-Labeled 1C1m-Fc, a New Tool for TEM-1 PET Imaging and Prediction of Lutetium-177-Labeled 1C1m-Fc Therapy Efficacy and Safety. <i>Cancers</i> , 2021, 13, 5936.	3.7	2
5	ARRONAX Cyclotron: Setting up of In-House Hospital Radiopharmacy. <i>BioMed Research International</i> , 2020, 2020, 1-6.	1.9	1
6	TE1PA as Innovating Chelator for ⁶⁴ Cu Immuno-TEP Imaging: A Comparative in Vivo Study with DOTA/NOTA by Conjugation on 9E7.4 mAb in a Syngeneic Multiple Myeloma Model. <i>Bioconjugate Chemistry</i> , 2019, 30, 2393-2403.	3.6	18
7	Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches. <i>Frontiers in Medicine</i> , 2019, 6, 124.	2.6	20
8	What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between ⁸⁹ Zr- and ⁶⁴ Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2564.	4.1	22
9	Synthesis of <i>C</i> -functionalized TE1PA and comparison with its analogues. An example of bioconjugation on 9E7.4 mAb for multiple myeloma ⁶⁴ Cu-PET imaging. <i>Organic and Biomolecular Chemistry</i> , 2018, 16, 4261-4271.	2.8	21
10	Comparison of Immuno-PET of CD138 and PET imaging with ⁶⁴ CuCl ₂ and ¹⁸ F-FDG in a preclinical syngeneic model of multiple myeloma. <i>Oncotarget</i> , 2018, 9, 9061-9072.	1.8	29
11	Sensitivity of pretargeted immunoPET using ⁶⁸ Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with ¹⁸ FDG PET-CT. <i>Oncotarget</i> , 2018, 9, 27502-27513.	1.8	12
12	Cyclam te1pa for ⁶⁴ Cu PET imaging. Bioconjugation to antibody, radiolabeling and preclinical application in xenografted colorectal cancer. <i>RSC Advances</i> , 2017, 7, 9272-9283.	3.6	15
13	Radioimmunoconjugates for treating cancer: recent advances and current opportunities. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 813-819.	3.1	27
14	Pretargeting for imaging and therapy in oncological nuclear medicine. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2017, 2, 6.	3.9	41
15	Immuno-PET for Clinical Theranostic Approaches. <i>International Journal of Molecular Sciences</i> , 2017, 18, 57.	4.1	50
16	Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and ⁶⁸ Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1505-1511.	5.0	61
17	Ionic liquid supported organotin reagents to prepare molecular imaging and therapy agents. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 2121-2126.	2.8	21
18	Radioimmunotherapy for Treatment of Acute Leukemia. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 135-146.	4.6	31

#	ARTICLE	IF	CITATIONS
19	Alpha Particles Induce Autophagy in Multiple Myeloma Cells. <i>Frontiers in Medicine</i> , 2015, 2, 74.	2.6	7
20	Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model. <i>Frontiers in Medicine</i> , 2015, 2, 76.	2.6	41
21	Improvement of the Targeting of Radiolabeled and Functionalized Liposomes with a Two-Step System Using a Bispecific Monoclonal Antibody (Anti-CEA \times Anti-DTPA \times In). <i>Frontiers in Medicine</i> , 2015, 2, 83. ^{2,6}		7
22	Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients. <i>Frontiers in Medicine</i> , 2015, 2, 84.	2.6	29
23	Therapeutic Efficacy of Alpha-RIT Using a ²¹³ Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal Carcinomatosis. <i>Frontiers in Medicine</i> , 2015, 2, 88.	2.6	17
24	Combining α -Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction. <i>PLoS ONE</i> , 2015, 10, e0130249.	2.5	33
25	A pretargeting system for tumor PET imaging and radioimmunotherapy. <i>Frontiers in Pharmacology</i> , 2015, 6, 54.	3.5	41
26	Tumor Immunotargeting Using Innovative Radionuclides. <i>International Journal of Molecular Sciences</i> , 2015, 16, 3932-3954.	4.1	51
27	⁹⁰ Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. <i>Lancet Haematology</i> , the, 2015, 2, e108-e117.	4.6	36
28	New synthesis of phenyl-isothiocyanate C-functionalised cyclams. Bioconjugation and ⁶⁴ Cu phenotypic PET imaging studies of multiple myeloma with the te2a derivative. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 11302-11314.	2.8	32
29	Abstract P5-01-01: Pretargeted immuno-PET with an anti-carcinoembryonic antigen (CEA) bispecific antibody (BsMAb) and ⁶⁸ Ga-labeled hapten-peptide compared to conventional imaging and FDG-PET in metastatic breast cancer patients (BC): First results. , 2015, ,		1
30	Improvement in imaging of metastatic breast cancer (BC) with a novel pretargeted immuno-PET targeting CEA: First clinical results.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11059-11059.	1.6	0
31	Radioiodinated and astatinated NHC rhodium complexes: Synthesis. <i>Nuclear Medicine and Biology</i> , 2014, 41, e23-e29.	0.6	10
32	Radiolabeling of HTE1PA: A new monopicolinate cyclam derivative for Cu-64 phenotypic imaging. In vitro and in vivo stability studies in mice. <i>Nuclear Medicine and Biology</i> , 2014, 41, e49-e57.	0.6	36
33	Radioimmunoconjugates for the Treatment of Cancer. <i>Seminars in Oncology</i> , 2014, 41, 613-622.	2.2	65
34	H2Me-do2pa: an attractive chelator with fast, stable and inert ^{nat} Bi ³⁺ and ²¹³ Bi ³⁺ complexation for potential α -radioimmunotherapy applications. <i>Chemical Communications</i> , 2014, 50, 12371-12374.	4.1	26
35	EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2175-2185.	6.4	31
36	Guidance on current good radiopharmacy practice for the small-scale preparation of radiopharmaceuticals using automated modules: a European perspective. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 615-620.	1.0	44

#	ARTICLE	IF	CITATIONS
37	Antitumor Immunity Induced after β Irradiation. <i>Neoplasia</i> , 2014, 16, 319-328.	5.3	71
38	Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. <i>Frontiers in Oncology</i> , 2013, 3, 177.	2.8	30
39	Abstract A53: Alpha particles and induction of an antitumor immune response.. , 2013, , .		0
40	Radionuclide Metabolic Therapy. , 2013, , .		0
41	Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1185-1192.	5.0	74
42	Radiolabeled Antibodies for Cancer Imaging and Therapy. <i>Methods in Molecular Biology</i> , 2012, 907, 681-697.	0.9	61
43	Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC). <i>Tumor Biology</i> , 2012, 33, 601-606.	1.8	14
44	Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients. <i>Tumor Biology</i> , 2012, 33, 679-688.	1.8	48
45	Unprecedented incorporation of β -emitter radioisotope ^{213}Bi into porphyrin chelates with reference to a daughter isotope mediated assistance mechanism. <i>Chemical Communications</i> , 2011, 47, 8554.	4.1	12
46	The intraportal injection model for liver metastasis. <i>Nuclear Medicine Communications</i> , 2011, 32, 147-154.	1.1	17
47	Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors. <i>EJNMMI Research</i> , 2011, 1, 20.	2.5	44
48	Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 2153-2164.	6.4	25
49	Efficient synthesis of new tetradentate ligands with potential applications for ^{64}Cu PET-imaging. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 924-927.	2.2	5
50	Antibody-Hapten Recognition at the Surface of Functionalized Liposomes Studied by SPR: Steric Hindrance of Pegylated Phospholipids in Stealth Liposomes Prepared for Targeted Radionuclide Delivery. <i>Journal of Drug Delivery</i> , 2011, 2011, 1-9.	2.5	10
51	Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1049-1062.	6.4	113
52	Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma. <i>Cancer</i> , 2010, 116, 1053-1058.	4.1	25
53	Comparative Toxicity and Efficacy of Combined Radioimmunotherapy and Antiangiogenic Therapy in Carcinoembryonic Antigen-Expressing Medullary Thyroid Cancer Xenograft. <i>Journal of Nuclear Medicine</i> , 2010, 51, 624-631.	5.0	19
54	Feasibility of the radioastatination of a monoclonal antibody with astatine- ^{211}At purified by wet extraction. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2008, 51, 379-383.	1.0	21

#	ARTICLE	IF	CITATIONS
55	Binding Activities and Antitumor Properties of a New Mouse/Human Chimeric Antibody Specific for GD2 Ganglioside Antigen. <i>Clinical Cancer Research</i> , 2007, 13, 5613s-5620s.	7.0	19
56	Purification of [18F]-fluoro-l-thymidine ([18F]-FLT) for positron emission tomography imaging. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2007, 45, 154-157.	2.8	6
57	A simple and efficient method to label l-fucose. <i>Tetrahedron Letters</i> , 2006, 47, 6869-6873.	1.4	2
58	Synthesis and evaluation of a novel samarium-153 bifunctional chelating agent for radioimmunotargeting applications. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2006, 49, 109-123.	1.0	6
59	High-Activity Radio-Iodine Labeling of Conventional and Stealth Liposomes. <i>Journal of Liposome Research</i> , 2006, 16, 91-102.	3.3	29
60	Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. <i>Journal of Nuclear Medicine</i> , 2006, 47, 247-55.	5.0	88
61	Cancer radioimmunotherapy with alpha-emitting nuclides. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 601-614.	6.4	148
62	Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 901-909.	6.4	18
63	Influence of trans-1,2-diaminocyclohexane structure and mixed carboxylic/phosphonic group combinations on samarium-153 chelation capacity and stability. <i>European Journal of Medicinal Chemistry</i> , 2004, 39, 467-472.	5.5	11
64	Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial. <i>Clinical Cancer Research</i> , 2003, 9, 3973S-81S.	7.0	37
65	Efficient Synthesis of a New Potential Chelating Agent for Radioimmunotherapy. <i>Synlett</i> , 2002, 2002, 2080-2082.	1.8	0
66	Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma. <i>Cancer</i> , 2002, 94, 1202-1209.	4.1	60
67	Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 267-74.	4.1	31
68	Synthesis of a novel bifunctional chelating agent for actinium complexation. <i>Tetrahedron Letters</i> , 2000, 41, 7207-7209.	1.4	12
69	Rhenium-188-labeled anti-neural cell adhesion molecule antibodies with 2-iminothiolane modification for targeting small-cell lung cancer. <i>Annals of Nuclear Medicine</i> , 2000, 14, 173-179.	2.2	10
70	Pharmacokinetics and biodistribution of samarium-153-labelled OC125 antibody coupled to CITCDTPA in a xenograft model of ovarian cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 560-567.	2.1	17
71	Comparative targeting of human colon-carcinoma multicell spheroids using one- and two-step (bispecific antibody) techniques. , 1996, 67, 883-891.		10
72	Bifunctional Antibodies for Radioimmunotherapy. <i>Hybridoma</i> , 1995, 14, 125-128.	0.6	18

#	ARTICLE	IF	CITATIONS
73	Does immunoscintigraphy serve clinical needs effectively? Is there a future for radioimmunotherapy?. European Journal of Nuclear Medicine and Molecular Imaging, 1992, 19, 205-13.	2.1	21
74	Use of multi-cell spheroids of ovarian carcinoma as an intraperitoneal radio-immunotherapy model: Uptake, retention kinetics and dosimetric evaluation. International Journal of Cancer, 1992, 50, 984-991.	5.1	28